《大行報告》大摩升微軟(MSFT.US)目標價至465美元 季績充分體現GenAI領先地位
摩根士丹利發表報告指,微軟(MSFT.US)季績充分體現GenAI領先地位,其中第二財季收入約10億美元,每股盈測達0.16美元,均勝於預期。期內,Azure增長達28%,高於預期,公司指引意味著第三財季達28%,亦高於預期。管理層指出,此貢獻大致上受推理所驅動,但公司提供Azure AI服務擁有廣泛優勢的證據,包括新客戶勢頭、Azure OpenAI勢頭及GitHub副駕駛勢頭等。
展望第三財季,該行指公司指引Azure收入增長維持穩定,加上人工智能持續發展,該穩定性由研發簡易優化對比性所推動,同時管理層對此優化轉變趨勢持正面看法。
該行將微軟目標價由450元上調至465元,維持其評級為「增持」。(ca/w)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.